Ken Griffin Regulus Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 15, 2025	BUY	$0.97 - $1.75 $9,603 - $17,325	9,900 New	9,900 $17,000
Q3 2024 Nov 14, 2024	BUY	$1.46 - $1.9 $17,812 - $23,180	12,200 Added 71.76%	29,200 $45,000
Q2 2024 Aug 14, 2024	SELL	$1.79 - $2.8 $16,468 - $25,760	-9,200 Reduced 35.11%	17,000 $30,000
Q1 2024 May 15, 2024	BUY	$1.13 - $2.88 $13,311 - $33,926	11,780 Added 81.69%	26,200 $75,000
Q4 2023 Feb 14, 2024	SELL	$1.21 - $1.44 $3,872 - $4,608	-3,200 Reduced 18.16%	14,420 $18,000
Q3 2023 Nov 14, 2023	SELL	$1.27 - $1.76 $4,572 - $6,336	-3,600 Reduced 16.97%	17,620 $24,000
Q2 2023 Aug 14, 2023	BUY	$0.87 - $1.75 $7,221 - $14,525	8,300 Added 64.24%	21,220 $31,000
Q1 2023 May 15, 2023	SELL	$0.79 - $1.61 $5,688 - $11,592	-7,200 Reduced 35.79%	12,920 $10,000
Q4 2022 Feb 14, 2023	SELL	$1.17 - $1.85 $362 - $573	-310 Reduced 1.52%	20,120 $27,000
Q3 2022 Nov 14, 2022	BUY	$1.35 - $2.39 $27,580 - $48,827	20,430 New	20,430 $35,000

4.71M

25K

Ticker RGLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,634,400
Market Cap $119M
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.